Skip to Content
Morningstar

Agios Pharmaceuticals Inc AGIO

Morningstar Rating
Unlock
Stock XNAS Rating as of
$43.22 −0.40 (0.92%)
View Full Chart
As of Cboe BZX Real-Time Price Open
Unlock our analysis with Morningstar Investor
Start Free Trial

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

View History
AGIO is trading at a 53% premium.
Price
$43.45
Fair Value
$24.68
Uncertainty
Very High
1-Star Price
$782.72
5-Star Price
$87.86
Economic Moat
Hqtk
Capital Allocation
—
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AGIO is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$43.62
Day Range
$42.95–44.33
52-Week Range
$19.80–49.07
Bid/Ask
$43.17 / $43.26
Market Cap
$2.45 Bil
Volume/Avg
90,249 / 797,829

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
82.96
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
—

Company Profile

Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
386
Website
https://www.agios.com

Comparables

Valuation

View More
Metric
AGIO
TGTX
ALVR
Price/Earnings (Normalized)
 —17.94—
Price/Book Value
 3.3317.330.74
Price/Sales
 82.969.30—
Price/Cash Flow
 —32.56—
Price/Earnings
AGIO
TGTX
ALVR

Financial Strength

Metric
AGIO
TGTX
ALVR
Quick Ratio
 11.642.7618.38
Current Ratio
 12.843.6218.48
Interest Coverage
 —4.45—
Quick Ratio
AGIO
TGTX
ALVR

Profitability

Metric
AGIO
TGTX
ALVR
Return on Assets (Normalized)
 −30.62%27.97%−52.15%
Return on Equity (Normalized)
 −34.68%73.42%−65.46%
Return on Invested Capital (Normalized)
 −35.50%42.25%−59.04%
Return on Assets
AGIO
TGTX
ALVR
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Biotechnology Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
JwlgvqcjkRhjl$639.3 Bil
 Vertex Pharmaceuticals Inc
VRTX
HmcrmwskZkgnf$121.9 Bil
 Regeneron Pharmaceuticals Inc
REGN
SjtckcnwNmmxnj$115.8 Bil
 Moderna Inc
MRNA
JglffmrcfSlb$46.4 Bil
 Alnylam Pharmaceuticals Inc
ALNY
YtfpfblgBthbc$31.2 Bil
 argenx SE ADR
ARGX
BzjzqrzyWfppd$26.4 Bil
 BioNTech SE ADR
BNTX
RvhrjcvxYdfdz$19.4 Bil
 Biomarin Pharmaceutical Inc
BMRN
YcstkyhjFzcdw$15.9 Bil
 United Therapeutics Corp
UTHR
HpsbkpzvrDxmjt$14.1 Bil
 Incyte Corp
INCY
KhkltwclCscsmk$12.1 Bil

Sponsor Center